Driving groundbreaking research. Improving lives.
Helping people with an MPN live a better quality of life as we work toward answers to prevention, progression and a cure for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms.
What is Primary Myelofibrosis (MF)?
Primary Myelofibrosis (MF)
PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.
What is Essential Thrombocythemia (ET)?
Essential Thrombocythemia (ET)
Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.
What is Polycythemia Vera (PV)?
Polycythemia Vera (PV)
The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.
Recent News
Patients and Caregivers Play an Active Role in MPN Research
MPN NEWS | March 18, 2024
Today, it is essential for patients to be involved with research and drug developers as they progress through the various stages of bringing a new therapy to market. MPN Research Foundation (MPNRF) is committed to ensuring that patient participation is more than a ticked box for drug approval. We actively work to incorporate the patient… Read More »Patients and Caregivers Play an Active Role in MPN Research
UK Study Details Skin Cancer Risks for MPN Patients
MPN NEWS | March 15, 2024
Several studies have confirmed the association of ruxolitinib (a JAK inhibitor) with increased risk of non-melanoma skin cancers (NMSCs). A study published in a January 2024 issue of the journal Blood reports on just how serious the risks might be, specifically among patients living with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). And… Read More »UK Study Details Skin Cancer Risks for MPN Patients
Understanding who develops which MPN and why
MPN NEWS | March 15, 2024
Jyoti Nangalia, MBBS, PhDWellcome Sanger Institute It is known that JAK2 mutations are found in “healthy” people around the world, particularly in older individuals. Most of them don’t acquire characteristics of myeloproliferative neoplasms (MPNs). The question is why do some people with the mutation develop an MPN while others don’t. Researchers from the Wellcome… Read More »Understanding who develops which MPN and why
Ready to do more?
Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.
Stay Connected
With an investment today, you can accelerate research for better outcomes.
By supporting MPN Research Foundation, you’re also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.